Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
02 January 2018Website:
http://www.cuebiopharma.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 20:54:39 GMTDividend
Analysts recommendations
Institutional Ownership
CUE Latest News
Cue Biopharma (CUE) has identified a hammer chart pattern, suggesting that the stock has found support following a recent decline in value. This, along with an increase in earnings estimate revisions, could signal a potential turnaround for the stock in the near future.
Cue Biopharma, Inc. (NASDAQ:CUE ) Q4 2023 Earnings Conference Call April 8, 2024 4:30 PM ET Company Participants Daniel Passeri - CEO Matteo Levisetti - Chief Medical Officer Anish Suri - President & Chief Scientific Officer Kerri-Ann Millar - CFO Conference Call Participants Stephen Willey - Stifel Ren Benjamin - JMP Operator Greetings and welcome to the Cue Biopharma Investor Update call. At this time, all participants are in listen-only mode.
BOSTON, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specific T cells, announced today that it will take part in a fireside chat at the JMP Securities Hematology and Oncology Summit being held virtually from December 5-6, 2023.
Cue Biopharma, Inc. (NASDAQ:CUE ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Daniel Passeri - CEO Matteo Levisetti - Chief Medical Officer Anish Suri - President & Chief Scientific Officer Kerri-Ann Millar - CFO Conference Call Participants Reni Benjamin - JMP Securities Ted Tenthoff - Piper Sandler Operator Good afternoon, ladies and gentlemen, and welcome to the Cue Biopharma Third Quarter 2023 Earnings Call. At this time, all lines are in listen-only mode.
Cue Biopharma, Inc. (NASDAQ:CUE ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Dan Passeri - Chief Executive Officer Anish Suri - President & Chief Scientific Officer Matteo Levisetti - Chief Medical Officer Kerri Millar - Chief Financial Officer Conference Call Participants Ted Tenthoff - Piper Sandler Ren Benjamin - JMP Securities Operator Greetings, and welcome to the Cue Biopharma Investor Update Call. At this time, all participants are in a listen-only mode.
Now is a great time to start accumulating top biotech stocks. The biotech boom is red-hot.
Most of the biggest biotech stocks on the market started off as unknown penny stocks. Look at Axsome Therapeutics (NASDAQ: AXSM ), for example.
What type of business is Cue Biopharma?
Cue Biopharma Inc is a biopharmaceutical company working in the clinical stage. It is developing a new patented class of biological drugs for selective modulation of the human immune system to treat a wide range of cancers and autoimmune diseases. Its lead drug candidate includes CUE-101, a variant form of interleukin-2 cytokine and T-cell antigen for targeting and activating cancer-specific T cells associated with HPV-related cancer. Other products in development include CUE-102, CUE-103, CUE-400, and CUE-401. Cue Biopharma, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
What sector is Cue Biopharma in?
Cue Biopharma is in the Healthcare sector
What industry is Cue Biopharma in?
Cue Biopharma is in the Biotechnology industry
What country is Cue Biopharma from?
Cue Biopharma is headquartered in United States
When did Cue Biopharma go public?
Cue Biopharma initial public offering (IPO) was on 02 January 2018
What is Cue Biopharma website?
https://www.cuebiopharma.com
Is Cue Biopharma in the S&P 500?
No, Cue Biopharma is not included in the S&P 500 index
Is Cue Biopharma in the NASDAQ 100?
No, Cue Biopharma is not included in the NASDAQ 100 index
Is Cue Biopharma in the Dow Jones?
No, Cue Biopharma is not included in the Dow Jones index
When does Cue Biopharma report earnings?
The next expected earnings date for Cue Biopharma is 09 August 2024